|
Zanubrutinib for the treatment of MYD88 wild-type WM: a substudy of the phase 3 ASPEN trial
|
|
The race to stymie BTK: zanu zings
|
|
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
|
|
Response and Survival Outcomes to Ibrutinib monotherapy for patients with WM on & off Clinical Trials
|
|
A prognostic index predicting survival in transformed WM
|
|
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WM: the ASPEN study
|
|
Partial response or better at six months is prognostic of superior progression-free survival in WM patients treated with Ibrutinib
|
|
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated WM
|
|
Management of Waldenstrom's Macroglobulinemia in 2020
|
|
A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WM
|
|
Long-Term Follow-up of Ibrutinib Monotherapy in Symptomatic, Previously Treated patient with WM
|
|
Ixazomib, Dexamethasone, and Rituximab in treatment-naive patients with WM: Long-term follow-up
|
|
Genomic Landscape of WM and its Impact on Treatment Strategies
|
|
Genomic evolution of ibrutinib-resistant clones in WM
|
|
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas
|
|
Epigenomics in Waldenstrom Macroglobulinemia
|
|
Discovery of a Selective Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma
|
|
CXCR4 mutational status does not impact outcomes in patients w WM treated with proteosome inhibitors
|
|
CXCR4 in WM: chances and challenges
|
|
Consensus Treatment recommmendations from the 10th International Workshop for WM
|
|
Consensus Statement on the Management of WM Patients During COVID19 Pandemic
|
|
Comparative genomics of CXCR4MUT and CXCR4WT single cells in WM
|
|
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID19 infected patients
|
|
A prognostic index predicting survival in transformed WM
|
